drugset
drugset / Trial / NCT02354261

Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

NCT02354261 ↗

Phase 2 Completed 38 enrolled HedgePath Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The study will assess the safety and efficacy of SUBA-Cap in subjects with Basal Cell Carcinoma Nevus Syndrome.

Timeline

Start
2015-08-07
Primary completion
2019-03
Completion
2019-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 300 mg Oral

Indications

basal cell carcinoma